explore -WSS

explore

author：focus 2025-08-23 18:38:57 - browse：48476

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Transgender sports debate: Physicians say bans are health issue

focus

WSS

FDA seeks to regulate lab

Covid’s new normal has set in amid another rise in cases

The unintended consequences of overturning Roe v. Wade

House panel takes first step toward fixing drug shortages

FDA seeks to regulate lab

White House Covid adviser calls on docs to combat misinformation

leisure time

explore

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Shingles, which affected Dianne Feinstein, is on the rise

Anesthesiologist group: stop taking Ozempic before surgery

Why the quest to eradicate polio has stumbled

At least 13 dead in Texas as scorching temps continue

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Heart attack and stroke risk calculators need revising

Akili changes sales model for its ADHD video game treatment

BioMarin wins approval for gene therapy to treat hemophilia A

Assistant physicians can help address the primary care shortage

focus

David Liu startup to focus on CRISPR delivery

Intercept Pharmaceuticals sells itself for less than $1 billion

Biogen shutters digital health group, ends Apple study, in cost cutting move

Data show record exodus of life scientists from academia

How the Dana

Medicare drug price negotiation program allowed for now

knowledge

focus

focus

focus